RCEL Similar Chart Price Prediction
The price of RCEL is predicted to go up -1.84%, based on the high correlation periods with HCA. The similarity of these two price pattern on the periods is 97.85%.
RCEL
HCA
Down: -1.84%Similarity: 97.85%
RCEL Revenue Forecast
RCEL EPS Forecast
RCEL FAQs
What is revenue forecast for next quarter？
What is eps forecast for next quarter？
RCEL Analyst's Forecast
Jason Kolbert
D. Boral Capital
Strong Buy
Price Target
$25
Upside
+93.65%
D. Boral Capital initiated coverage of Avita Medical with a Buy rating and $25 price target. Avita's Recell technology has shown "promising results" in clinical trials for a variety of soft tissue and skin-related indications and Avita is "poised for significant growth" from expanding market penetration into trauma wounds, surgical wounds, and "slowly but surely chronic wounds" as awareness of the technology increases and adoption grows in hospitals and burn centers worldwide, the analyst tells investors.